Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens.
Comparison
Delta (B.1.617.2)
Omicron (B.1.1.529)
SARS-CoV-2 rapid antigen test
Variants of concern
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
26
01
2022
accepted:
27
04
2022
pubmed:
21
5
2022
medline:
31
1
2023
entrez:
20
5
2022
Statut:
ppublish
Résumé
Omicron is rapidly spreading as a new SARS-CoV-2 variant of concern (VOC). The question whether this new variant has an impact on SARS-CoV-2 rapid antigen test (RAT) performance is of utmost importance. To obtain an initial estimate regarding differences of RATs in detecting omicron and delta, seven commonly used SARS-CoV-2 RATs from different manufacturers were analysed using cell culture supernatants and clinical specimens. For this purpose, cell culture-expanded omicron and delta preparations were serially diluted in Dulbecco's modified Eagle's Medium (DMEM) and the Limit of Detection (LoD) for both VOCs was determined. Additionally, clinical specimens stored in viral transport media or saline (n = 51) were investigated to complement in vitro results with cell culture supernatants. Ct values and RNA concentrations were determined via quantitative reverse transcription polymerase chain reaction (RT-qPCR). The in vitro determination of the LoD showed no obvious differences in detection of omicron and delta for the RATs examined. The LoD in this study was at a dilution level of 1:1,000 (corresponding to 3.0-5.6 × 10 In this study, RATs from various manufacturers were investigated, which displayed no obvious differences in terms of analytical LoD in vitro and RAT positivity rates based on clinical samples comparing the VOCs omicron and delta. However, differences between tests produced by various manufacturers were detected. In terms of clinical samples, a focus of this study was on specimens with high virus concentrations. Further systematic, clinical and laboratory studies utilizing large datasets are urgently needed to confirm reliable performance in terms of sensitivity and specificity for all individual RATs and SARS-CoV-2 variants.
Identifiants
pubmed: 35596057
doi: 10.1007/s15010-022-01844-5
pii: 10.1007/s15010-022-01844-5
pmc: PMC9122478
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-245Investigateurs
Vadim Balakin
(V)
Bernadett Bartha-Dima
(B)
Katja Bengs
(K)
Anja Berger
(A)
Kerstin Boll
(K)
Anja Carl
(A)
Jürgen Christian
(J)
Juliana Drdlicek
(J)
David Eisenberger
(D)
Jennifer Flechsler
(J)
Lars Gerdes
(L)
George Githure
(G)
Janani Govindaswamy
(J)
Christine Hupfer
(C)
Johannes Lutmayr
(J)
Gabriele Margos
(G)
Roswitha Müller
(R)
Silke Nickel
(S)
Melanie Pavlovic
(M)
Sven Pecoraro
(S)
Daniel Reichwald
(D)
Robert Ethan Rollins
(RE)
Isabel Sahm
(I)
Melanie Schauer
(M)
Sandra Schmidt
(S)
Gesine Schulze
(G)
Anika Schülein
(A)
Eva-Maria Schürmann
(EM)
Nelly Scuda
(N)
Judith Seebach
(J)
Stefanie Singer
(S)
Thorsten Stellberger
(T)
Christian Tuschak
(C)
Pia Zimmermann
(P)
Informations de copyright
© 2022. The Author(s).
Références
Med Microbiol Immunol. 2022 Jun;211(2-3):105-117
pubmed: 35187580
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Euro Surveill. 2021 Nov;26(44):
pubmed: 34738515
Open Forum Infect Dis. 2022 Jan 28;9(3):ofac022
pubmed: 35169591
Microbiol Spectr. 2022 Aug 31;10(4):e0085322
pubmed: 35938792
J Clin Microbiol. 2022 Feb 16;60(2):e0247921
pubmed: 34936477
Microorganisms. 2021 Sep 16;9(9):
pubmed: 34576862
Anaesth Crit Care Pain Med. 2022 Feb;41(1):100998
pubmed: 34902630
Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1303-1308
pubmed: 33512617